Dossier · Private startup · 3 independent sources
MNDL Bio
Last updated: Jul 31, 2026
MNDL Bio is an Israeli synthetic-biology startup building an AI- and biophysics-based platform for designing DNA constructs that improve recombinant-protein expression and scale-up. Its commercial proposition is to make gene-expression optimization more predictive, reducing wet-lab iteration for biotech, biopharma, food, and industrial-biotechnology teams.
Visit WebsiteCompany Overview
MNDL Bio addresses the design stage of the design-build-test-learn cycle for recombinant-protein production. Its platform produces host-optimized, synthesis-ready DNA sequences while preserving the target protein's amino-acid sequence. The company says it optimizes the full genetic architecture rather than applying codon changes alone, including expression-critical sequence elements such as promoters and untranslated regions. Its technical foundation combines mechanistic or biophysical models of gene expression with machine-learning and generative methods. The official site describes more than 15 years of underlying research led by CSO Prof. Tamir Tuller, validation across 10 or more host organisms, and more than 25 expression projects; these are company-reported figures and should be tested against customer data during diligence.
The immediate customer problem is expensive and unpredictable expression. A protein that is scientifically promising may still fail commercially because it expresses poorly, is unstable in its host, or requires too many construct iterations before a process can scale. MNDL Bio positions its software and associated technical workflow for biotech and biopharma developers, enzyme and food-tech companies, synthetic-biology teams, and other groups that need more protein per run or a shorter route from sequence to production. Its public website reports yield improvements ranging from 1.5x to 30x depending on the protein, host, and context, while named testimonials describe specific gains in bacterial and cell-free systems. Those claims are encouraging signals, but they are not a substitute for independently reproducible benchmarks, a clear baseline, or evidence that gains survive process development.
The market is crowded with substitutes at several layers. Customers can use internal bioinformatics teams, gene-synthesis vendors' optimization services, CROs and biofoundries, or broader design software. Companies such as Twist Bioscience, IDT, GenScript, TeselaGen, Arzeda, and Ginkgo Bioworks cover parts of the design-to-build workflow, though they differ in business model and technical scope. MNDL Bio's potential edge is the combination of host-aware whole-construct design, biophysical priors for data-limited settings, and an output that is intended to move directly into synthesis and cloning. That edge will be durable only if the company demonstrates repeatable improvement across protein classes and hosts, protects the underlying methods and data, and delivers an enterprise workflow that is faster and easier to adopt than an incumbent's in-house process.
Commercialization appears early but active. Public sources identify the company as founded in 2023 by Steve Grün, Eran Miller, and Tamir Tuller, and report a pre-seed financing of approximately $2 million led by Earth & Beyond Ventures with CPT Capital also identified as an investor. LinkedIn currently lists a 2–10 person organization, while the company site names a small scientific, product, and commercial team. MNDL Bio has also appeared in the Ignite DeepTech program and in industry events and profiles. The company describes a transition from technology delivered as a service toward a scalable software platform. Key diligence questions are whether the product is already repeatably self-serve, how many paying customers or active projects exist, what retention and gross-margin profile the service work produces, and whether customer data can improve the models without creating confidentiality or IP friction.
The defense and national-security case is indirect but credible as a resilience thesis. Better construct design could support distributed or sovereign production of enzymes, food proteins, research reagents, and other critical biomolecules, reducing dependence on fragile international supply chains and shortening the time needed to stand up new biological manufacturing routes. The platform is not presented publicly as a weapons, pathogen, surveillance, or defense-procurement product, and there is no verified public evidence of defense contracts. Its relevance therefore comes from enabling bioindustrial capacity and supply assurance, not from direct military end use. That distinction keeps the dual-use case meaningful without overstating it.
Dual-Use Assessment
MNDL Bio has substantive commercial and strategic-resilience applicability because the same construct-design technology can improve production of food proteins, enzymes, biomaterials, and other critical biomolecules. The defense connection is indirect: the public record supports a bioindustrial-capacity and supply-chain-resilience thesis, but does not verify defense customers, military deployment, or weapons-related use.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
MNDL Bio fits the site's early-stage deep-tech and dual-use thesis as an enabling layer for more reliable biomanufacturing. The strongest evidence is its scientific provenance, named technical team, reported pre-seed backing, and public customer-oriented performance examples. The priority signal remains conditional: diligence should establish independently reproducible gains, paying-customer conversion, software-versus-services economics, IP ownership, data rights, and the degree to which the product is deployable without bespoke scientific support.
Strategic Value to U.S.-Israel Alliance
MNDL Bio could improve the reliability, cost, and geographic flexibility of protein and enzyme production by moving more optimization into computation before expensive experiments and scale-up. That supports food and industrial resilience and could help establish sovereign bioindustrial capacity. Its strategic value is enabling and infrastructural rather than a verified direct-defense capability.
Key Technologies
- Mechanistic biophysical models of gene expression
- Machine-learning and generative DNA design
- Whole-construct promoter, UTR, and coding-sequence optimization
- Host-aware sequence engineering across microbial and other expression systems
- Synthesis-ready DNA sequence generation
- Genomic and multi-omics data integration
- Expression-yield and genetic-stability optimization
Use Cases & Applications
- Recombinant therapeutic and research-protein expression
- Industrial enzyme production and process scale-up
- Precision-fermentation and alternative-protein development
- Cell-free protein-expression optimization
- Bio-based materials and biomolecule manufacturing
- Rapid evaluation of new production hosts
- Resilient or distributed production of strategically important biomolecules
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work; the research methodology documents how evidence is graded, what counts as an independent source, and why some profiles are excluded from search indexing.
This record lists 7 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- MNDL Bio home Official company positioning, product claims, use cases, testimonials, and named performance ranges.
- MNDL Bio technology page Official description of the biophysical and AI approach, research base, host validation, and reported project count.
- MNDL Bio about page Official founder, team, advisory, and contact information.
- MNDL Bio LinkedIn company profile Current public company profile listing 2024 founding, Tel Aviv headquarters, and 2-10 employees; also records current ecosystem activity.
- CTech company profile Reports the 2023 founding, approximately $2M raised, pre-seed status, investors, and early company/product context.
- Startup Nation Finder profile Independent ecosystem profile corroborating 2023 founding, early-stage status, Tel Aviv-area location, employee range, funding history, and founders.
- Times of Israel Ignite DeepTech coverage Reports MNDL Bio's participation in the Intel-backed Ignite startup program.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
MNDL Bio may matter as a Health & BioTech entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify technical claims
- Verify regulatory/export-control issues
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies MNDL Bio's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- What would disconfirm the priority signal: weak customer references, thin technical differentiation, poor capital efficiency, or limited allied-market access?
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.